Genetic Polymorphism of GSTP1: Prediction of Clinical Outcome to Oxaliplatin/5-FU-based Chemotherapy in Advanced Gastric Cancer.
10.3346/jkms.2010.25.6.846
- Author:
Qing Fang LI
1
;
Ru Yong YAO
;
Ke wei LIU
;
Hong Ying LV
;
Tao JIANG
;
Jun LIANG
Author Information
1. Treatment and Research Center of Oncology, The Affiliated Hospital of Medical College of Qingdao University, Qingdao, China. qfmy4812@sina.com
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Polymorphism;
Glutathione S-Transferase pi;
Oxaliplatin;
Stomach Neoplasms
- From:Journal of Korean Medical Science
2010;25(6):846-852
- CountryRepublic of Korea
- Language:English
-
Abstract:
The aim of this study was to evaluate the predictive value of the polymorphism Glutathione S-transferase P1 (GSTP1) Ile(105)Val on oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. Patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated. GSTP1 Ile(105)Val polymorphism was detected by TaqMan-MGB probe allelic discrimination method. Response to treatment was assessed by disease controlled rate. Time to progression, overall survival and toxicities were recorded. Final patient outcomes were as follows: the allele frequencies of GSTP1 were (105)Ile/(105)Ile 52%, (105)Ile/(105)Val 41% and (105)Val/(105)Val 7%. For patients with (105)Ile/(105)Ile and those with at least one (105)Val allele, disease control rate was 39% and 71% (P=0.026), respectively; median time to progression was 4.0 and 7.0 months (P=0.002); median overall survival time was 7.0 and 9.5 months (P=0.002). Neurological toxicity was more frequently occurred in patients with two (105)Ile alleles (P=0.005). In conclusion, patients with at least one (105)Val allele have better prognosis and response to oxaliplatin/5-FU-based regimen as first-line treatment for patients with advanced gastric cancer.
